Antares Pharma Stock News

Wall Street analysts forecast that Antares Pharma, Inc. (NASDAQ:ATRS) will announce earnings of $0.01 per share for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Antares Pharmas earnings, with the lowest EPS estimate coming in at $0.01 and the highest estimate coming in at $0.02. Antares Pharma reported earnings of []

EWING, N.J., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, today announced the divestiture of OTREXUP ® (methotrexate) injection for the treatment of rheumatoid arthritis to a subsidiary of Assertio Holdings, Inc., a commercial pharmaceutical company, for a total cash consideration of $44.0 million inclusive of OTREXUP ® WIP and finished inventory. Under the terms of the asset purchase agreement, Antares will receive an initial payment of $18.0 million at closing plus two additional time-based payments totalling $26.0 million in 2022.

Trailing 12 Month Reported Revenues of Otrexup Were $15.5 Million

Antares Pharma, Inc. (NASDAQ:ATRS)s share price reached a new 52-week low on Friday . The stock traded as low as $3.13 and last traded at $3.14, with a volume of 23712 shares traded. The stock had previously closed at $3.26. ATRS has been the subject of several recent research reports. HC Wainwright lowered their price []

Antares Pharma, Inc. (NASDAQ:ATRS) shares hit a new 52-week low during mid-day trading on Friday . The stock traded as low as $3.13 and last traded at $3.14, with a volume of 23712 shares traded. The stock had previously closed at $3.26. A number of research firms have recently weighed in on ATRS. HC Wainwright []

Antares Pharma, Inc. (NASDAQ:ATRS) was the target of a significant decline in short interest during the month of November. As of November 15th, there was short interest totalling 2,660,000 shares, a decline of 34.2% from the October 31st total of 4,040,000 shares. Approximately 1.6% of the companys shares are sold short. Based on an average []

The research study presented here is a brilliant compilation of different types of analysis of critical aspects of the global Needle Free Diabetes Management market. It sheds light on how the global Needle Free Diabetes Management Market is expected to

Wall Street analysts predict that Antares Pharma, Inc. (NASDAQ:ATRS) will report earnings of $0.01 per share for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Antares Pharma’s earnings, with the lowest EPS estimate coming in at $0.01 and the highest estimate coming in at $0.02. Antares Pharma posted earnings per […]

During the last session, Antares Pharma Inc. (NASDAQ:ATRS)s traded shares were 0.31 million, with the beta value of the company hitting 1.49. At the end of the trading day, the stocks price was $3.42, reflecting an intraday gain of 0.29% or $0.01. The 52-week high for the ATRS share is $5.07, that puts it down Is Antares Pharma Inc. (NASDAQ: ATRS) Hit More of the Losses Given A -48.25% Dip From High? Read More »

Pharmaceutical Drug Delivery Market research report gives a thorough idea about the current scenario of the global market, recent developments, product launches, joint ventures, capacity, production value, mergers, and acquisitions based on several market dynamics. It gives key measurements, the

Equities analysts predict that Antares Pharma, Inc. (NASDAQ:ATRS) will announce $0.01 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Antares Pharmas earnings, with estimates ranging from $0.01 to $0.02. Antares Pharma posted earnings of $0.03 per share during the same quarter last year, which indicates []

EWING, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to virtually present and host investor meetings at the Piper Sandler 33 rd Annual Virtual Healthcare Conference being held on November 29-December 2, 2021.

State Street Corp lowered its holdings in Antares Pharma, Inc. (NASDAQ:ATRS) by 26.7% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,450,854 shares of the specialty pharmaceutical companys stock after selling 1,260,131 shares during the period. State Street Corp owned approximately 2.03% of Antares Pharma worth []

Antares Pharma Inc. (NASDAQ:ATRS) price on Friday, November 19, rose 3.82% above its previous days close as an upside momentum from buyers pushed the stocks value to $3.53. A look at the stocks price movement, the close in the last trading session was $3.40, moving within a range at $3.39 and $3.56. The beta value Antares Pharma Inc. (ATRS) Has Recovered 19.26% From Its Low: Is This The Beginning Of A Trend? Read More »

DUBLIN, Nov. 18, 2021 /PRNewswire/ -- The "Global Auto Injector Market Outlook 2030" report has been added to ResearchAndMarkets.com''s offering. The market is estimated to garner a revenue of close to USD 11350 Million by the end of 2030, up from a revenue of about USD 3120 Million in the